Share to
New Reagent for Detecting the CAR Positive Rate of Anti-(G4S)n (B02H1) Monoclonal Antibody
Email:
htm0086@vip.163.com
Still deciding? Let’s start with a sample.Contact us!
Category
- Description
-
Product Background Overview
A CAR is an engineered receptor designed to modulate and redirect immune cell responses toward tumor-associated antigens of intrinsic origin. This receptor is a chimeric protein composed of four principal components: an extracellular antigen-binding domain (e.g., a single-chain variable fragment or scFv), a spacer or hinge domain, a transmembrane domain, and at least one intracellular signaling domain. The successful integration of these components enables CAR-expressing immune cells to recognize specific antigens and kill tumor cells.
During the discovery and preclinical research phases, when engineering CAR-X cells, scientists must verify cellular functionality by monitoring the surface expression of the CAR. Most existing detection methods rely on reagents that bind to the extracellular domain of the CAR and exploit specific sequences within the scFv, the variable heavy-chain domain of the hinge region, or the variable light-chain domain. Depending on the class of CAR-X detection reagent used, the available solutions often lack sufficient specificity, are difficult to integrate into multiplex flow cytometry panels, or are limited to detecting only a single CAR.
Currently, common methods for detecting CAR expression include using Protein L, target antigens, tag-specific antibodies, anti-idiotype antibodies (ADA), and co-expression of GFP or tEGFR; however, each of these approaches has its own advantages and limitations, and some are not suitable for practical applications.
In 2010, two patients with hematologic malignancies became the first participants in a clinical trial of CAR-T cell therapy at the Perelman School of Medicine at the University of Pennsylvania, and their cancers achieved complete remission that same year. More than a decade later, research published in Nature and based on up to 10 years of follow-up data show that CAR-T cells can still be detected in patients’ bodies 10 years after infusion. Owing to their high selectivity, localized high concentrations, and customizable nature, cell therapies have ushered in a new chapter in cancer immunotherapy.
CAR-T Cell Expansion and Persistence in Two Patients
Data sources: Nature, Zhiyin Global Biopharmaceutical Project Database
The manufacturing process for CAR-X cell therapies is complex and involves numerous quality-control steps. As an essential component of quality assurance for CAR-X therapy, the assay for detecting the positive expression rate of CAR-X currently lacks a standardized protocol. The Anti-(G4S)n (B02H1) monoclonal antibody, a broadly applicable CAR detection reagent, can directly identify and confirm the presence of CAR regardless of its antigen specificity. By recognizing the flexible (G4S)n linker, this antibody can bind to CARs with diverse specificities expressed on the cell surface; such CARs all contain a (G4S)n spacer (n ≥ 2) in their extracellular scFv domain.
Based on clinical needs and industry pain points, the HeYouSheng Bio team launched this unique product—Anti-(G4S)n linker (B02H1) mAb—domestically for the first time four months ago. The product has received unanimous recognition from customers, leading to stable and ongoing collaborations.
Anti-GSlinker (B02H1) It has the following characteristics:
1. Versatility: It is a validated, universal CAR positivity assay that accelerates drug development by eliminating unnecessary and time-consuming steps.
2. Universality: Applicable to CAR assays for all targets (including (G4S)n, n≥2); applicable to CAR assays for different antibody types (including (G4S)n, n≥2).
3. Interference-free: Unaffected by antigen interference, enabling more accurate detection of the CAR ratio.
4. High sensitivity: It exhibits excellent detection efficiency at both extremely high and extremely low concentrations.
The anti-(G4S)n (B02H1) monoclonal antibody is a validated and certified product, currently available in four formats: unlabelled antibody and fluorescently labeled antibodies (FITC/PE/APC). Domestic spot supply (within 1–2 weeks); convenient pre- and post-sales service. Customers are welcome to inquire.
Item number Product Name Specifications GS-ARNC25 Anti-(G4S)n (B02H1)mAb 125 μL GS-ARNC100 Anti-(G4S)n (B02H1)mAb 500 μL GS-ARFT25 Anti-(G4S)n (B02H1)mAb(FITC) 125 μL GS-ARFT100 Anti-(G4S)n (B02H1)mAb(FITC) 500 μL GS-ARPE25 Anti-(G4S)n (B02H1)mAb(PE) 125 μL GS-ARPE100 Anti-(G4S)n (B02H1)mAb(PE) 500 μL GS-ARAP25 Anti-(G4S)n (B02H1)mAb(APC) 125 μL GS-ARAP100 Anti-(G4S)n (B02H1)mAb(APC) 500 μL Corresponding isotype control antibody product ：
Item number Product Name Specifications RIC-NC25 Rabbit IgG Isotype Control 125 μL RIC-NC100 Rabbit IgG Isotype Control 500 μL RIC-FT25 Rabbit IgG Isotype Control (FITC) 125 μL RIC-FT100 Rabbit IgG Isotype Control ( FITC ) 500 μL RIC-PE25 Rabbit IgG Isotype Control (PE) 125 μL RIC-PE100 Rabbit IgG Isotype Control (PE) 500 μL RIC-AP25 Rabbit IgG Isotype Control (APC) 125 μL RIC-AP100 Rabbit IgG Isotype Control (APC) 500 μL Product Usage Information
【Application】 Flow cytometry (live)
[Dilution Ratio] 1:50–1:200
[Save] Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at 2–8°C. Do not aliquot the antibody.
[Source/Isotype] Rabbit IgG1
【Specificity/Sensitivity】 Anti-(G4S)n Rabbit mAb can detect the level of heterologous expression of scFv-based CARs containing (G4S)n linkers (n ≥ 2).
[Species Reactivity] All expected species
[Source/Purification] Monoclonal antibodies were generated by immunizing animals with synthetic peptides containing 2 to 5 tandem repeats of Gly4Ser.
We would like to express our sincere gratitude to both new and existing customers for their support of this innovative product. By working together to explore and validate novel approaches, we have not only achieved cost reductions and efficiency gains but also gained tremendous confidence in HeYouSheng. Whether preclinical or clinical users, customers have promptly shared their experimental data and results, offering overwhelmingly positive feedback and evaluations. HeYouSheng Biotechnology will continue to strive for excellence, live up to the trust placed in us, relentlessly innovate, deliver truly valuable and differentiated products and services, empower our industry partners, and jointly advance the development of the cell therapy field.
All the data presented below are kindly provided by our client. Thank you for your support!
Data Point 1: CAR Positive Expression Rate Assay (Clinical Case)
Data Point 2: CAR Positive Expression Rate Assay (Preclinical Case)
Data Point 3: Comparison Chart with a Major International Competitor’s Testing
Trial samples are still being accepted.
Anti-(G4S)n (B02H1) mAb – Download product documentation for various fluorescently labeled versions:
G4S-FITC 125μL COA+Datasheet.pdf
G4S-FITC 500μL COA+Datasheet.pdf
G4S-APC 125μL COA+Datasheet.pdf
G4S-APC 500μL COA+Datasheet.pdf
G4S-NC 125μL COA+Datasheet.pdf
G4S-NC 500μL COA+Datasheet.pdf
Related document downloads:
G4S-PE 500μL COA+Datasheet
G4S-NC 500μL COA+Datasheet
G4S-NC 125μL COA+Datasheet
G4S-FITC 125μL COA+Datasheet
G4S-APC 125μL COA+Datasheet
G4S-PE 125μL COA+Datasheet
G4S-APC 500μL COA+Datasheet
G4S-FITC 500μL COA+Datasheet
Consult Now
Please note: Kindly provide your contact information, and our dedicated professionals will get in touch with you as soon as possible!
